| abstract |
Administration of IL-21 results in a reduction of the autoimmune response, thereby providing a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that can be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease , Atopic dermatitis, and asthma. The pharmaceutical composition may comprise an IL-21 polypeptide and an active fragment thereof. |